Understanding the complex relationship between the Rh blood group system and hemolytic disease of the fetus and newborn (HDFN) is key to preventing life-threatening reactions during pregnancy and transfusion, according to a study published recently in the European Journal of Haematology.
This large-scale study of 5,050 patients in China found that comprehensive Rh typing and genetic testing can help predict and prevent such complications, leading to safer, more personalized blood transfusions.
“Genetic testing can accurately determine the blood type and molecular mechanism, revealing the polymorphism of genes and providing a strong foundation for clinical blood transfusion,” stated this study’s authors.
These researchers used microcolumn gel methods and genetic sequencing to identify Rh blood group antigens and irregular antibodies. They discovered that nearly all patients—5030 of 5050—were D-positive, with only 20 initially screened as D-negative.
Read more about testing and diagnosis of HDFN
Genetic analysis revealed that 11 of those D-negative individuals had RHD gene deletions, while the remaining 9 carried all 10 RHD exons, indicating new D variants. These results suggest that standard serologic tests can miss rare genetic variants, potentially putting patients at risk for hemolytic reactions or HDFN if mismatched blood is used.
Among the 70 antibodies detected, 49 were from the Rh system, representing 70% of all antibodies found. Anti-E antibodies were the most common, followed by anti-c and anti-C. While anti-D antibodies cause most cases of HDFN in White populations, this study found them to be less frequent among Chinese patients, likely because D-negative individuals are rare in China. Still, hemolytic transfusion reactions and HDFN caused by anti-E, anti-c, and anti-C antibodies remain a serious concern.
This study’s results reinforce that differences in Rh antigen distribution between populations affect the likelihood of immune response. Because of this, patients receiving repeated transfusions are at higher risk of developing antibodies that attack transfused blood cells or a fetus’s red cells during pregnancy. Identifying Rh variants early helps clinicians select compatible blood and avoid complications.
By combining genetic testing with large-scale blood typing, clinicians can move toward “Transfusionomics,” a data-driven approach integrating genomics, proteomics, and other omics technologies. This emerging field could help predict immune compatibility, guide transfusion decisions, and improve maternal and newborn health outcomes.
For patients, these advances could mean a future with fewer transfusion reactions, safer pregnancies and greater confidence that the blood used for their transfusion is the right match.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
